To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

This study has been completed.
Sponsor:
Information provided by:
Sandoz
ClinicalTrials.gov Identifier:
NCT00913549
First received: June 2, 2009
Last updated: June 3, 2009
Last verified: June 2009
  Purpose

To demonstrate the relative bioequivalency study of dosage forms of Clemastine 2.68 mg tablets.


Condition Intervention Phase
Allergy
Drug: Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
Drug: Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

Resource links provided by NLM:


Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence based on AUC and Cmax [ Time Frame: 19 days ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: December 1989
Study Completion Date: January 1990
Primary Completion Date: January 1990 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
Drug: Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
Experimental: 2
Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
Drug: Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)

  Eligibility

Ages Eligible for Study:   19 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00913549

Sponsors and Collaborators
Sandoz Inc.
Investigators
Principal Investigator: James C. Kisicki, M.D. Harris Laboratories, Incorporated
  More Information

No publications provided

Responsible Party: Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc.
ClinicalTrials.gov Identifier: NCT00913549     History of Changes
Other Study ID Numbers: 239-04
Study First Received: June 2, 2009
Last Updated: June 3, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Sandoz:
Antihistamine

Additional relevant MeSH terms:
Clemastine
Antipruritics
Dermatologic Agents
Therapeutic Uses
Pharmacologic Actions
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Allergic Agents

ClinicalTrials.gov processed this record on August 28, 2014